ESR1 and autosomal dominant polycystic kidney disease: This class of drugs degrades the estrogen receptor, acting as an antagonist independent of tissue type, but can cause venous thrombo‐embolism as a side effect and are not suitable for patients with a eGFR<30 ml/1.73m/min, which may be an issue in ADPKD patients.53